Novartis reported $3.84B in Cost of Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbvie ABBV:US USD 4.17B 57M
Alcon AG ALC:SW USD 998M 26M
Amgen AMGN:US USD 1.75B 159M
Artemis Alpha ATS:LN GBP 507K 125K
AstraZeneca AZN:LN USD 2.51B 393M
Bayer BAYN:GR EUR 4.77B 521M
Biogen BIIB:US USD 570.9M 101.4M
Bristol Myers Squibb BMY:US USD 2.52B 167M
Eli Lilly And LLY:US USD 1.55B 31M
Fresenius FRE:GR EUR 7.86B 105M
Fresenius Medical Care FME:GR EUR 3.65B 88.3M
Galapagos GLPG:NA EUR 4.14M 1.75M
Gilead Sciences GILD:US USD 1.4B 1000K
GlaxoSmithKline GSK:LN GBP 2.18B 209M
Hikma Pharmaceutical HIK:LN USD 662M 72M
Johnson & Johnson JNJ:US USD 7.76B 29M
Lonza Group LONN:SW CHF 2B 213M
Merck MRK:GR EUR 2.28B 137M
Merk MRK:US USD 3.36B 519M
Novartis NOVN:VX USD 3.84B 180M
Novartis NVS:US USD 3.84B 180M
Orion ORNBV:FH EUR 139.3M 3.2M
Pfizer PFE:US USD 9.82B 3.73B
Philips PHIA:NA EUR 3.2B 621M
Recordati REC:IM EUR 154.92M 2.52M
Regeneron Pharmaceuticals REGN:US USD 540.6M 222.8M
Roche Holding ROG:VX 8.95B 613M